Company / Cash & Equivalents
Kymera Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$357.0M
FY2025
5-year range
$31.0M / $357.0M
FY2021-FY2025
Trend
+196.9%
vs FY2024
Sector context
#55 of 207
Health Care
What the data says
At $357M, Kymera Therapeutics, Inc.'s cash & equivalents ranks #55 of 207 in the Health Care sector. Cash & Equivalents has increased for 4 consecutive years, from $31M in FY2021 to $357M in FY2025.
Based on SEC 10-K filings.
$357M in FY2025 with a 5-year CAGR of +36.3%.
Improved from $110M to $357M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +73.5%
- 5-Year CAGR
- +36.3%
- 10-Year CAGR
- -
Sector benchmark
#55 of 207 in Health CareTop 27% of 207This company $357.0M Sector average $669.5M
▼
-46.7% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +36.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 196.9% year-over-year.
- Ranks #55 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $357.0M | +196.9% |
| FY2024 | $120.3M | +9.4% |
| FY2023 | $110.0M | +60.8% |
| FY2022 | $68.4M | +120.6% |
| FY2021 | $31.0M | -59.2% |
| FY2020 | $76.0M | +0.0% |
| FY2019 | $76.0M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026